tbuckley/cabot-search huggingface dataset:
1185MO Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials
Authors: M.M.M. Weber, L. Apostolidis, S. Krug, A. Rinke, B. Gruen, P. Michl, T.M. Gress, D. Wagner, W. Roth, E. Mettler, C. Ruckes, P.R. Galle, C. Fottner
Journal: Annals of Oncology (2023)
418P Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Authors: Q. Zhang, J. Wang, Q. Ouyang, X. Wang, D. Lin, J. Wang, L. Gan, Z. Ouyang, T. Xu, Y. Liu, Y. Lv
Journal: Annals of Oncology (2023)
382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Authors: N.U. Lin, V.F. Borges, M.R. Patel, M. Okera, J. Meisel, R. Wesolowski, T. Pluard, K.D. Miller, N.J. McCarthy, A.K. Conlin, R. Mahtani, D. Sabanathan, K.E. McCann, E. Roesch, G. Mathauda-Sahota, J. Schroeder, E.P. Hamilton
Journal: Annals of Oncology (2023)
416P Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Authors: S. Sehdev, C. Brezden-Masley, D. Soliman, K. El Ouagari, C. Biswas, M. Kalra, V. Sharma
Journal: Annals of Oncology (2023)
377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
Authors: S.A. Hurvitz, S. Modi, W. Li, Y.H. Park, W. Chung, S-B. Kim, J. Cortés, T. Yamashita, J. Pedrini, S-A. Im, L-M. Tseng, N. Harbeck, I. Krop, G. Curigliano, E. Mathias, J. Cathcart, A. Cagnazzo, S. Ashfaque, A. Egorov, F. André
Journal: Annals of Oncology (2023)
378O Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC)
Authors: M.K. Welslau, P. Fasching, L. Mueller, E. Belleville, L. Rieger, M-O. Zahn, B. Lex, L. Häberle, H. Tesch
Journal: Annals of Oncology (2023)
455P Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
Authors: R. Palumbo, G. Saltalamacchia, E. Quaquarini, B. Tagliaferri, C.M. Teragni, C. Barletta, M. Frascaroli, E. Biscaldi, A. Malovini, L.D. Locati, F. Sottotetti
Journal: Annals of Oncology (2023)
726P Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Authors: C.L. Ronchi, J. Lippert, G. Smith, B. Altieri, Y.S. Elhassan, L-S. Landwehr, A. Prete, S. Appenzeller, V. Chortis, S. Kircher, M. Asia, W. Arlt, M. Fassnacht
Journal: Annals of Oncology (2023)
734P Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)
Authors: P. Giannatempo, S. Nazzani, V. Bernasconi, M. Mego, I. Taglialatela, D. Bimbatti, S. Secondino, M. Claps, D. Biasoni, M. Catanzaro, M. Zimatore, T. Torelli, S. Stagni, A. Macchi, A. Tesone, P. Pedrazzoli, U. Basso, G. Procopio, F.G.M. De Braud, N. Nicolai
Journal: Annals of Oncology (2023)
415P Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
Authors: L. Cucciniello, C. Noto, S. Bolzonello, E. Molteni, L. Da Ros, B. Pastò, A. Franzoni, S. Spazzapan, S. Russo, L. Foffano, S. Buriolla, G. Targato, L. Allegri, A. Dri, S. Della Rossa, M. Bonotto, G. Damante, B. Belletti, L. Gerratana, F. Puglisi
Journal: Annals of Oncology (2023)
422P UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
Authors: G. Gullick, C. Owen, S. Cook, J. Helbrow, R. Squires, H.M. Reed, S. Park, E. Weir, F. Aquilina, N. Webber, E. Nye, C. Atkinson, C. Blair, A. Halstead, E. Daniels, A. Alves, S. Chew, W. Thomas, S. Spensley, T. Robinson
Journal: Annals of Oncology (2023)
725MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
Authors: V. Gambardella, J. Capdevila Castillon, Y. Kuboki, O. Alese, D. Morgensztern, C.M. Sayehli, M.F. Sanmamed, E. Arriola, Z. Oum' Hamed, E. Song, M. Studeny, M. Wermke
Journal: Annals of Oncology (2023)
461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial
Authors: J.L. Blum, G. Rocque, Y. Ji, T. Pluard, J. Migas, S. Lakhanpal, E. Jepsen, E. Gauthier, Y. Wang, M.Z. Montelongo, J. Cappelleri, C. Chen, M.S. Karuturi, D. Tripathy
Journal: Annals of Oncology (2023)
469P Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Authors: M. Torrente, B. Cantos, J.C. Sanchez Gonzalez, M. Mendez Garcia, B. Nunez Garcia, M. Blanco Clemente, M. Campos, B. Rodriguez Morilla, P.F. Almaida Pagan, C. Parejo, S.C. González González, C. Traseira Puchol, M. Martinez Cutillas, R. Aguado, Y. Garitaonaindía Díaz, A. González Sánchez, M.M. Sánchez del Corral, D.I. Ruiz de Domingo, M.I. Melero Cipres, M. Provencio Pulla
Journal: Annals of Oncology (2023)
479P Radiomics to predict HER2 status in breast cancer brain metastases
Authors: G. Griguolo, M. Gabelloni, R. Fusco, W. Jacot, M.C. Guarascio, R. Francischello, L. Bauchet, V. Granata, L. Faggioni, M. Bottosso, V. Rigau, M.V. Dieci, E. Neri, A. Darlix, V. Guarneri
Journal: Annals of Oncology (2023)
436P Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial)
Authors: H. Cao, T. Sun, Z. Li, M. Yan, X. Cui, C. Zhou, M. Jing, X. Guo, Y. Wang
Journal: Annals of Oncology (2023)
381O First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
Authors: J. Wu, J. Zhang, H. Li, X. Wang, Q.Y. Zhang, Y. Shi, None M. yan, Y. Pan, A. Shen, Q. Chen, Q. Rao, H. Wei, C. Li, L. Yang, Q. Huang, Z. Cao, Q. Wu
Journal: Annals of Oncology (2023)
472P Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Authors: J. Tobias, S. Högler, M. Kundi, D. Shih-Cheih Lin, Y. Chao, E. Garner-Spitzer, N. Ede, C. Zielinski, A. Good, U. Wiedermann
Journal: Annals of Oncology (2023)
424P Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
Authors: X. Hu, J. Cao, Y. Teng, H. Li, L. Zhang, Q. Ouyang, W. Xie, Y. Pan, Z. Song, X. Ling, X. Wu, J. Xu, L. Li, L. Ren, H. Wang, D. Zhou, J. Luo
Journal: Annals of Oncology (2023)
1602P Simulation training for compassionate extubation in the pediatric intensive care unit
Authors: N. Fernandez
Journal: Annals of Oncology (2023)

Background: Sarcopenia is a common condition among cancer patients.The aim of this study is to investigate the potential relationship between sarcopenia and hematologic toxicity in cancer patients by evaluating skeletal muscles with computed tomography (CT) and ultrasound (US) before chemotherapy.
316P Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Authors: L. Hohmann, K. Sigurjónsdóttir, A. Bosch, D.F. Nacer, S. Veerla, J. Häkkinen, J. Vallon-Christersson, Å. Borg, Y. Memari, H. Davies, S. Nik-Zainal, J. Staaf
Journal: Annals of Oncology (2023)
410P Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)
Authors: J. Lemaitre, E. Chazard, P-Y. Cren, L. Lebellec, N. Penel, C. Cheymol
Journal: Annals of Oncology (2023)
408P Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
Authors: H. Li, H. Jiang, G. Song, R. Ran, J. Wang, X. Wang, J. Huang, J. Feng, L. Zhang, A. Zang, H. Yang, Y. Pan, X. He, M. Donng, Y. Tong, Z. Wang, Z. Shao
Journal: Annals of Oncology (2023)
380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial
Authors: Q. Ouyang, Y. Yin, L. Song, M. Yan, X. Wu, Z. Tong, Y. Liu, X. Wang, X. Jin, Y. Diao, G. Liu, J. Ge, J. Li
Journal: Annals of Oncology (2023)
846P Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Authors: S. Assaad, J-Y. Blay, H. Crochet, P-E. Heudel, S. Bouam, M-P. Revel, G. Chassagnon, C. Bigenwald, L. Albiges, F. André, E. Battistella, O. Teboul, D. Pescia, B. Bertrand, E. D'Amico-Gandia, W. Kandeil, M. Guillet, A. Remorino, D. Dellamonica, N. Paragios
Journal: Annals of Oncology (2023)
423P A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Authors: H.W. Wei, C. Qi, None S. Kun, W. Xi, H. Jian, L. Jian, W. Li, W. Fan, X. Chen, L. Ni, H. Yi, None C. lan
Journal: Annals of Oncology (2023)
406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
Authors: S. Lopez-Tarruella Cobo, A. Stradella, P. Tolosa Ortega, S. Antolín-Novoa, M. Santisteban Eslava, J. Garcia-Corbacho, A.L. Guerrero Zotano, M. Ruiz Borrego, M. Muñoz Caffarel, N. Losic, E. Jaensson Gyllenbäck, P. Skoog, H. Johansen Blanco, J.J. Soto-Castillo, M. Alva Bianchi, C. Reboredo Rendo, M. Casas, N. Caparroso, S. Bezares Montes, I. Garcia Ribas
Journal: Annals of Oncology (2023)
478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Authors: A. Palazzo, A. Toss, R. Graffeo, A. Fontana, M. Lambertini, F. Pantaleo, M. Perachino, M. Nerone, N. Bianco, P. Vici, L. de Marchis, N. Staropoli, L. Rinaldi, A. Lai, G.P. Spinelli, E. Di Monte, F. Giotta, A. Gennari, L. Cortesi, E. Bria
Journal: Annals of Oncology (2023)
413P Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
Authors: M. Martin Jimenez, S. Hilz, A. Collier, A. Chibly, J. Sohn, A. Bardia, E. Lim, M. Chavez Mac Gregor, J. Martinalbo, P.D. Pérez-Moreno, H.M. Moore
Journal: Annals of Oncology (2023)
414P Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
Authors: I.F. Michelon, M. Silveira Vilbert, A.D. Marinho, C.E.D.R. Castro, M.I. Dacoregio, C. Stecca, L.R. Soares
Journal: Annals of Oncology (2023)
1262MO Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
Authors: G. Eberst, J. Henriques, M. Monchatre, E. Giroux-Leprieur, E. Kelkel, A. Bizieux Thaminy, P. Ravier, P. Thomas, S. Bayle, C. Audigier Valette, H. Berard, F. Desliers, A. Lagrange, P. Bonnefoy, A. Langlais, D. Vernerey, A. Anota, F. Morin, V. Westeel
Journal: Annals of Oncology (2023)
311P Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Authors: R. Kaur, S.L. Powell, M. Artigas, I. Borovova, P. Gadiya, A. Hsu, L. Kidd, D. Rosenfeld, M.M. Saeed, E. Scarelli, M. Wahib
Journal: Annals of Oncology (2023)
463P Impact of two waves of Sars-Cov-2 outbreak on the clinical presentation and outcomes of newly referred breast cancer cases at AP-HP: A retrospective multicenter cohort study
Authors: S. Priou, E. Guével, G. Lamé, J. Wassermann, R. Bey, C. Uzan, G. Chatellier, Y. Belkacémi, X. Tannier, S. Guillerm, R. Flicoteaux, J. Gligorov, A. Cohen, M-A. Benderra, L. Teixeira, C. Daniel, C. Tournigand, E. Kempf
Journal: Annals of Oncology (2023)
471P Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Authors: C. Paratore, M. Audisio, S. Bombaci, M. Bungaro, R. Dionisio, G. Ferrari, E. Gaudino, L. Grassi, A. Hotca, C. Loddo, G. Manuguerra, E. Manzin, S. Novello, G. Numico, I. Persano, C. Sculli, P. Sperone, A.A. Valsecchi, G. Zucchini, G. Vellani
Journal: Annals of Oncology (2023)
823O Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
Authors: M. Jongen-Lavrencic, A. Bajel, S. Garciaz, A. Maiti, S. Fleming, S. De Button, G.A. Huls, K. Jensen, S. Ziti-Ljajic, D. Draganov, F. Rotolo, C. Palu, J. Courta, W. Passe-Coutrin, K. Traudtner, T. Wagenaar, G. Abbadessa, A. Selwyn Stein
Journal: Annals of Oncology (2023)
451P Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort
Authors: B.E. Gosalbez Pequeno, A.L.V. Matos, A.M. Nogal Dias, S. Braga, L.I. Pinto, A. Pêgo, C.D. Abreu, M.I.R. Ferreira, P.F. Gago, I. Faustino, I.M. Matos Pina, C.P. Marques, J.L.C. Passos-Coelho, F.P. Branco, J.C.D.L. Simões, I.V. Vaz Luis, F. Schmitt, L. Costa, M.J.M. Vergueiro, D. Bras
Journal: Annals of Oncology (2023)
1265P Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
Authors: S. Yan, J. Wang, B. Liu, X. Yang, C. Lyu, S. Li, Y. Wang, J. Bi, X. Li, Y. Tao, J. Chen, Y. Yang, N. Wu
Journal: Annals of Oncology (2023)
459P Progression-free survival (PFS) assessment by local investigators versus blinded independent central review (BICR) in randomized clinical trials (RCTs) in metastatic breast cancer (MBC): Is it really needed?
Authors: F. Jacobs, C. Molinelli, E. Agostinetto, D. Martins Branco, G. Nader Marta, M. Salmon, L. Ameye, M. Piccart, M. Lambertini, E. de Azambuja
Journal: Annals of Oncology (2023)
474P ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Authors: A.Y. Lin, O.I. Isaeva, D. Vessies, T. Deger, L. Voorwerk, V. Geurts, H. Horlings, J. Martens, L. Wessels, D. Van Den Broek, M. Kok
Journal: Annals of Oncology (2023)
417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Authors: V. Cogliati, E. Rossi, A. Turla, M. Ambroggi, R. Berardi, F. Borella, L. Coltelli, U.F.F. De Giorgi, A. Ferro, O. Garrone, M. Giordano, E. Landucci, M. Mazzotta, G. Moretti, R. Palumbo, P. Vici, F. Zustovich, F. Riva, S. Capici, M.E. Cazzaniga
Journal: Annals of Oncology (2023)
1187MO Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?
Authors: R.L. Libe, G. Coureau, A-S. Foucan, M. Haissaguerre, D. Drui, S. Grunenwald, F. Castinetti, S. Laboureau, C. Docao, F. Borson-Chazot, B. Goichot, L. Lamartina, O. Chabre, None S. moog, J. Bertherat, None A. tabarin, M. Faron, E. Baudin
Journal: Annals of Oncology (2023)
736P Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study
Authors: G. Baciarello, C. Brard, H. Baumert, U.F.F. De Giorgi, A. Flechon, P. Giannatempo, G. Gravis, F. Morelli, D. Pouessel, B. Vincenzi, C. Oing, S. Secondino, S. Ladoire, L. Crouzet, N. Naoun, S. Foulon, K. Fizazi
Journal: Annals of Oncology (2023)
374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Authors: A. Basu, S. Umashankar, M. Musthafa, T. Jones, K. Blevins, T. Brown, D. Heditsian, B. Parker, S. Brain, C. Simmons, T.J. Hieken, K. Ruddy, C. Mainor, S. Tevis, A. Blaes, H.S. Rugo, I. Dunn, M. Melisko, L. Esserman, D.L. Hershman
Journal: Annals of Oncology (2023)
411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Authors: F. Marmé, C. Brucker, T. Decker, P. Fasching, T. Göhler, C. Jackisch, J. Janssen, A. Koehler, K. Luedtke-Heckenkamp, None D. Lüftner, M. Van Mackelenbergh, A. Nusch, B. Rautenberg, M. Schmidt, T. Reimer, R. Weide, P. Wimberger, S. Maslanka Figueroa, C. Roos, A. Woeckel
Journal: Annals of Oncology (2023)
837P Phase II study of anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT: Drug characteristics, immunologic and genetic biomarkers associated with treatment outcome and toxicities
Authors: W.S. Kim, S.J. Kim, D.H. Yoon, H-S. Eom, D.H. Yang, S-S. Yoon, S.E. Yoon, H. Cho, E-Y. Lee, H.W. Lee, J-H. Jung, G-Y. Song, Y. Koh, S-H. Choi, Y. Park, J.R. Kim
Journal: Annals of Oncology (2023)
435P Phase II single arm study of durvalumab and olaparib (D+O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)
Authors: T. Fujii, S. Lipkowitz, A.D.S. Zimmer, E. Villanueva, B.B. Solarz, J-M. Lee
Journal: Annals of Oncology (2023)
1189P Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Authors: A. Di Mauro, F. Tatangelo, S. Tafuto, M. Cantile, U. Chianese, R. Benedetti, M. Conte, M. Cerrone, G. Scognamiglio, A. Nebbioso, L. Altucci
Journal: Annals of Oncology (2023)
470P Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Authors: M. Bergamini, R. Pedersini, C. Brentegani, V. Baluta, G. Schivardi, D. Cosentini, P. di Mauro, M. Zamparini, M. Laganà, V. Amoroso, L. Vassalli, A. Alberti, L. Laini, E.L. Simoncini, A. Berruti
Journal: Annals of Oncology (2023)
850P A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Authors: A.M. Luciano, J.F. Rodriguez-Vidal, A. Jiménez-Blaya, M. Fernández-Lajarín, M.L. Cayuela- Fuentes, M.D. Odero, D. Garcia-Moreno, V. Mulero-Mendez
Journal: Annals of Oncology (2023)
453P Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Authors: J. Zhou, X. Wu, J. Chen, L. Bian, S. Zhang, Z. Jiang, T. Wang
Journal: Annals of Oncology (2023)

At present, trastuzumab and pertuzumab has become the standard treatment for HER2-positive early breast cancer at high risk of recurrence and metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. There is currently no clinical trials exploring the efficacy of pyrotinib for HER2-positive advanced breast cancer after prior trastuzumab and pertuzumab. The aim of this study is to analyze the efficacy and safety of pyrotinib-based therapy in patients after prior trastuzumab and pertuzumab. The pathological and clinical data of 77 HER2-positive advanced breast cancer patients treated with pyrotinib after prior trastuzumab and pertuzumab were retrospectively analyzed. Observation indexes included PFS, CBR, ORRand adverse events. A total of 77 patients were enrolled in this study at the Breast Oncology Department of the Fifth Medical Center of the PLA General Hospital from February 2019 to March 2023. Median age of the patients was 52 years (28-73 years), 64.9% were HR positive, 63.6% had visceral metastases, and 27.3% had brain metastases. 50(64.9%) of the patients received pyrotinib combined with capecitabine, 8(10.4%) received pyrotinib combined with vinorelbine, 3(3.9%) received pyrotinib combined with nab-paclitaxel, and 16(20.8%) received pyrotinib combined with endocrine therapy. The median line of pyrotinib was 2 (1-7), the median number of anti-HER 2 targeted therapy was 2 (2-6). Median follow-up was 17.8 months (1.6-51.4months) by the data cutoff date (May 2023). The median PFS was 13.6 months (95%CI: 8.3-18.9). The ORR was 50.0% in the 56 patients with evaluable lesions,the CBR was 54.5%, and the mPFS was 10.8 months (95%CI: 7.7-13.9). 46 patients who progressed on prior trastuzumab and pertuzumab had evaluable lesions, the ORR was 43.5%, CBR was 69.6%, and the mPFS was 9.2 months (95%CI: 6.4-12.0). The most common adverse events was diarrhea in the study. This study first retrospectively analyze the value of pyrotinib in the era of dual anti-HER2 therapy, preliminarily showing good efficacy and safety of pyrotinib in patients after prior trastuzumab and pertuzumab.
724O EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
Authors: E. Baudin, S. Grisanti, C.W. Menke-van der Houven van Oordt, H. Haak, J. Capdevila Castillon, M. Fassnacht, V. Subbiah, C. Jimenez, C. de la Fouchardiere, J. Yachnin, D. Granberg, M. Kroiss, K.G. Daugaard, D. Cosentini, L. Lamartina, J-M. Paillarse, L. Aubergeon, J. Fagerberg, L. Chêne, A. Berruti
Journal: Annals of Oncology (2023)
328P Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique
Authors: V. Petry, R. Colombo Bonadio, K. Moutinho, L. Senna, L. Testa, M.C. Fragoso, M.D.P. Estevez Diz
Journal: Annals of Oncology (2023)
729P Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Authors: V. Andreasi, S. Partelli, M. Schiavo Lena, F. Muffatti, A. Battistella, D. Tamburrino, N. Pecorelli, S. Crippa, G. Balzano, C. Doglioni, M. Falconi
Journal: Annals of Oncology (2023)
373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS
Authors: D. Tripathy, J.L. Blum, M.S. Karuturi, S. McCune, S. Kurian, M.M. Moezi, D.M. Anderson, Y. Wang, M.Z. Montelongo, Z. Zhang, E. Gauthier, G. Rocque
Journal: Annals of Oncology (2023)
1186MO A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET)
Authors: S. Partelli, L. Landoni, M. Bartolomei, A. Zerbi, C.M. Grana, U. Boggi, G. Butturini, R. Casadei, C. Bassi, M. Falconi
Journal: Annals of Oncology (2023)
839P Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and glofitamab (glofit) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Authors: F.L. Locke, J.M. Chen, K. Chan, M.D. Ray, I. Zhang, S. Keeping, C. Fu, A.R. Patel, O.O. Oluwole
Journal: Annals of Oncology (2023)